FDA Approved: INMAZEB — Supplemental Application (Regeneron Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for INMAZEB, Regeneron's triple-monoclonal antibody therapy for Ebola virus disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• INMAZEB (ATOLTIVIMAB, MAFTIVIMAB, and ODESIVIMAB-EBGN)

Snippet

SUPPL AP for INMAZEB (ATOLTIVIMAB, MAFTIVIMAB, AND ODESIVIMAB-EBGN)